β-Blockers Influence Oncological Outcomes in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy Based on the Pathological Subtype: A Retrospective Cohort Study.

Ann Surg Oncol · 2025 · PMC12129865 · PMID 40131627

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

showed a trendp = 0.072so close (0.05 < p ≤ 0.1)

BB users showed a trend towards improved OS (HR 0.50, 95% CI 0.27–1.07; p = 0.072) (Fig. 2 c), with a median OS that was not reached and a 3-year survival of 58% versus a median OS of 34 months and a 3-year survival of 49% in BB non-users.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.